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Background: Countries must decide whether or not to replace primary cytology-based screening with primary
human papillomavirus (HPV)-based screening. We aimed to assess how primary screening for an HPV infection, a
sexually transmitted infection (STI), and the type of information included in the invitation letter, will affect screening
intention.
Methods: We randomized a representative sample of Norwegian women to one of three invitation letters: 1) Pap
smear, 2) HPV testing or 3) HPV testing with additional information about the nature of the infection. Intention to
participate, anxiety level and whether women intend to follow-up abnormal results were measured between groups
using chi-squared and nonparametric Kruskal-Wallis tests. Determinants of intention were explored using logistic
regression.
Results: Responses from 3540 women were representative of the Norwegian population with respect to age, civil
status and geographic location. No significant difference across invitation letters was found in women’s stated
intention to participate (range: 91.8-92.3%), anxiety (39-42% were either quite or very worried) or to follow-up after
an abnormal result (range: 97.1-97.6%). Strength of intention to participate was only marginally lower for HPV-based
invitation letters, albeit significant (p-value = 0.008), when measured on a scale. Only 36–40% of respondents given
the HPV invitations correctly understood that they likely had an STI.
Conclusions: We found that switching to primary HPV screening, independent of additional information about HPV
infections, is not likely to reduce screening participation rates or increase anxiety; however, women lacked the
ability to interpret the meaning of an HPV-test result.
Keywords: Mass screening, Human papillomavirus, Pap smear, Health policyBackground
High participation and follow-up rates of population-based
cervical cancer screening programs using cytology-based
methods (Pap smear) have been effective in reducing the
incidence and mortality of invasive cervical cancer in many
developed countries [1]. Since 1995, the Norwegian Coordi-
nated Cervical Cancer Screening Programme (NCCSP) has
sent reminder letters to women aged 25–69 who have not* Correspondence: emily.burger@medisin.uio.no
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unless otherwise stated.had a registered Pap smear within the last three years and a
second reminder is sent to women who have not had a reg-
istered smear within 12 months of the initial letter. The
NCCSP also sends reminder letters to encourage women to
follow-up with their physician in the case of an abnormal
or unsatisfactory result. Currently, 80% of targeted women
regularly participate in screening, while approximately 65-
70% of women with a high-grade abnormal result return
within one year [2].
Due to the causal link between cervical cancer and hu-
man papillomavirus (HPV), a common sexually transmit-
ted infection (STI), diagnostic tests, which explicitly detectLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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domized controlled trials have shown that primary HPV
testing can detect more high-grade precancerous lesions
than conventional or liquid-based cytology (LBC) [3].
While treatment for HPV is currently unavailable, cellu-
lar changes associated with the infection can be moni-
tored and treated to prevent invasive cervical cancer
from developing. In response, several countries are con-
sidering replacing primary cytology-based screening
with primary HPV-based screening. In Norway, an
HPV-based algorithm for women aged ≥34 has been
proposed [4] that involves primary HPV testing followed
by reflex LBC (i.e., retesting the same sample) for women
who test positive for high-risk HPV types. HPV testing
may also facilitate less frequent screening [5] (e.g., exten-
ding the primary interval from 3 to 6 years has been sug-
gested in Norway [4]).
Whether or not explicitly testing for an STI will affect
screening adherence in Norway is not known. As in
other countries, public understanding of HPV and its
role in cervical cancer development is poor [6]. The
most recent Norwegian survey [7] revealed that only one-
third of women reported knowledge of HPV. Though few
women may equate abnormal cytology results with sexual
activity, there may be different psychosocial outcomes be-
tween women who test positive for detectable cellular or
histological lesions and those who test positive for an
asymptomatic HPV infection [8]. Some women may con-
centrate on the sexual transmissibility of HPV rather than
its implications towards the development of cervical can-
cer. Fear, anxiety, distress and concern regarding sexual
behavior have been reported as the prominent emotional
reactions from testing positive for HPV [9-13]. Within
relationships, questions about trust and blame may also
arise [12]. In addition, women who link their positive
HPV test to sexual activity may experience guilt, stigma
and shame [14]; however, differences in psychosocial
outcomes between HPV and Pap smear testing often
converge within 6–12 months (implying that even if dif-
ferences in anxiety are initially detected, they are un-
likely to be long-lasting) [6,8]. The level of anxiety and
stress experienced by the women may also be a function
of understanding and how the results of a positive test
are communicated [15].
One potential concern is that some specific subgroups
may respond differently to primary HPV testing than
others. In a qualitative study performed in the United
States [16], women >55 years of age and married or
women who were not currently sexually active were less
likely to feel at risk of an infection with HPV. If primary
HPV testing is implemented, and women older than 55
or in stable relationships equate their current self-
perceived risk of having an STI with the need for HPV-
based testing, they may not believe they require screening.On the other hand, in the Netherlands, a population-
based randomized trial evaluated the efficacy of primary
co-testing (i.e., primary cytology in combination with
HPV testing) compared to cytology-based screening alone
and reported no decrease in the attendance rate [17].
However, it is not clear whether these results can be ex-
trapolated outside the context of a well-supported ran-
domized trial (i.e., women may have been more motivated
due to the possibility of more extensive surveillance of-
fered in a trial setting) or for an HPV test that is not taken
concomitantly with cytology, requiring women to rely
solely on HPV-based screening.
Intention to perform an action is often cited as the
most important predictor of behavioral performance or
one’s true actions [18] and can be perceived as one’s mo-
tivation to perform. We aim to explore whether an invi-
tation letter to a Pap smear screen (every three years)
versus HPV-based screening (every six years) and the
type of information included in the invitation letter influ-
ences women’s anxiety and intent to participate in screen-
ing and follow-up testing among Norwegian women.
Secondly, we explored determinants of intention to par-
ticipate in screening and investigated whether age- and
civil status-specific subgroups of women, respond differ-
ently to explicitly testing for an STI compared to testing
for abnormal cellular changes.
Methods
Study design
In 2011, we conducted a randomized web-based survey of
a representative sample of Norwegian women using TNS
Gallup’s active internet panel of more than 50,000 individ-
uals. Baseline demographic characteristics, knowledge of
cervical cancer and HPV infection, perceived risk of cer-
vical cancer and anxiety towards developing STIs were ob-
tained. To elicit the intent to participate in screening,
women were randomized to one of three versions of cer-
vical cancer screening invitation letters (Figure 1). The
first version of the invitation (herein referred to as the
“Pap letter”) used verbatim text from the current reminder
letter sent to women from the NCCSP recommending tri-
ennial Pap smear screening [2]. The second version
(herein referred to as the “HPV basic letter”) preserved
the wording of the Pap letter but stated that HPV testing
would replace Pap smear testing and informed women
that they would only need to be screened every six years
(to reflect the current proposal for primary HPV testing in
Norway [4]). The letter also informed women that in the
event of a positive HPV test, their same sample would be
retested for cellular changes (i.e., reflex LBC). The third
invitation letter (herein referred to as the “HPV expanded
letter”) was identical to the HPV basic letter, but included
additional information regarding the ease of transmission
of HPV as well as stating that it is possible to have the
Figure 1 Flow diagram. Women were randomized to one of three invitation letters according to: 1) conventional practice using Pap smear-based
screening (Pap letter), 2) to primary HPV testing with minimal information (HPV basic letter), or 3) to HPV testing with more explicit information about
HPV infections (HPV expanded letter).
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targeted women who may not believe they are at risk of
HPV due to age or current sexual behavior. All three let-
ters stated that cervical cancer is caused by an infection
with HPV and is transmitted sexually (See Additional file 1
for translated invitation letters). Lastly, women were
asked to read a letter, based on actual text from the
NCCSP, which provided information about a hypothet-
ical positive test result. We developed the survey using a
multi-stage, iterative process. We formulated the vi-
gnettes and questions to evaluate our objectives (in col-
laboration with stakeholders from the Cancer Registry
of Norway), using familiar and neutral language, and
included response categories that were mutually exclu-
sive and collectively exhaustive. At an early stage of
survey development, a convenience sample of women
(n = 55) provided feedback on question understanding,
interpretation and relevance. Finally, a link to the up-
dated electronic version of the survey was emailed to a
small sample of women from the TNS Gallup panel, in
which 107 provided feedback on the technical aspects
of survey administration, as well as an opportunity to
provide general open-ended comments.
In keeping with the proposed primary HPV testing
algorithm [4], women randomized to the HPV basic or
expanded letter were asked to imagine they were HPV-
positive and that there was evidence of abnormal cellular
changes, while women who received the Pap letter were
only told to imagine they had abnormal cellular changes.Questions explored willingness to participate in screen-
ing and follow-up testing, level of understanding and
anxiety associated with the positive test letter. Intention
was captured by binary response (yes/no), the strength
of intent to participate was elicited on a 10-point scale
(1: definitely not attend; 10: definitely attend) and anx-
iety was measured on a 5-point scale (1: not worried at
all; 5: very worried). Informed consent was obtained
from all study participants and de-identified for analysis.
The study design and materials were reviewed and ap-
proved by the regional ethical committee.
Participants
Following pilot work, a power calculation for a two-
sample comparison of proportions determined that 1075
respondents in each of the three randomized groups
(n = 3225 in total) would be needed for 80% power with
a significance level of 0.05, to detect a 3.5% difference
(experts deemed clinically important) between expressed
participation rates. Based on published estimates of the
prevalence of hysterectomized women in Norway [19],
we expected to exclude 5% of respondents aged 40–50
and 10% of respondents aged 50–60. The survey was sent
out to 6757 women, a random sample of women aged 25–
69 in the panel. A target response of 3801 women (56%)
was obtained within two weeks, after which the website
was inactivated. The response rate may be underesti-
mated, as some women who may have been willing to re-
spond did not have the opportunity to do so after the
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hysterectomized women (6.9%), the survey sample con-
sisted of 3540 women.
Data analysis
We calculated proportions for binary responses and means
for the scale responses. We conducted Chi-squared tests
of statistical significance for the difference between
proportions and nonparametric analysis of variance (Kruskal-
Wallis) to test the differences between groups for ques-
tions measured on a continuous scale. Odds ratios
(ORs) were derived from univariable and multivariable
logistic regression models for the binary dependent variable
of intent to participate. The dependent variable was set to
equal 1 if the respondent intended to participate, and to
zero if they did not intend to participate. Independent
variables were selected to reflect author hypotheses and
factors, which have been associated with screening par-
ticipation in previous studies. In addition to the main ef-
fects, we studied whether invitation letter type interacts
with age (25–39, 40–59, 60–69) and civil status (single vs.
cohabiting/married) with regard to participation rate. The
α-level was set at 0.05. All data was analyzed in STATA,
release 12 (StataCorp, College Station, TX).
Results
The mean age of the final sample of 3540 women was
45.1 years. The baseline demographic characteristics were
evenly distributed among the randomized groups (Table 1)
and generally representative of the Norwegian population
for age, geographic location, level of income and civil sta-
tus; however, the sample was slightly over-represented by
higher educated women.
Questions eliciting general knowledge and anxiety
(Table 2) indicated that 42% of the respondents identi-
fied the primary cause of cervical cancer as a virus and
approximately half (53%) of the women reported having
previously heard of HPV. Of those women who had
heard of HPV, 82% identified HPV as an STI. Nearly all
women (93%) felt that Pap smears were either quite im-
portant or very important for the prevention of cervical
cancer and 94% reported having had at least one previ-
ous Pap smear. The majority of women (63%) stated
they were not very worried about developing cervical
cancer, and 88% stated that they were not worried about
contracting an STI. The proportion of women who were
least anxious towards contracting an STI peaked among
the oldest age group (95%) as well as among women in
committed relationships (93%). We found no significant
difference in women’s intent to participate in screening
(Pap letter: 92.3%, HPV basic letter: 91.8%, HPV ex-
panded letter: 92.2%) or follow-up (Pap letter: 97.6%,
HPV basic letter: 97.1%, HPV expanded letter: 97.2%)
between the invitation letters when captured by binaryresponse (Table 3). When the strength of intention was
elicited on a scale, the mean intent to participate in
screening (Pap letter: 8.40, HPV basic letter: 8.29, HPV
expanded letter: 8.24) and follow-up (Pap letter: 9.34,
HPV basic letter: 9.14, HPV expanded letter: 9.16) were
marginally lower for those women who received the
HPV invitations, albeit significant (p-value = 0.008 and
p-value = 0.002, respectively). Though anxiety linked to
an abnormal result was present (approximately 39-42%
were either quite or very worried), women did not worry
significantly more or less between the invitation letters
(p-value = 0.184). However, the ability to correctly inter-
pret a positive result was lacking; only 37% of women
randomized to the HPV basic letter and 40% of women
randomized to the HPV expanded letter understood
their positive HPV test indicated they had an STI.
Women were equally as likely to reveal their abnormal
Pap smear or HPV-positive result to their partner; how-
ever, up to 5% fewer women who received the positive
HPV result, in addition to abnormal cellular changes,
stated they would tell a close friend (p-value = 0.01),
compared to the women who were given only an abnor-
mal Pap smear result. After the inclusion of relevant co-
variates, logistic regression confirmed that the odds of
participating were not statistically different after receiv-
ing different versions of the invitation letter (Table 4).
Socio-demographic factors were significantly associ-
ated with intention to participate in the univariable
models, though effects did not remain significant in the
multivariable model (see Additional file 1 Appendix
Table). Women were more likely to state an intention to
participate 1) stated that they had received a previous
Pap smear (OR 3.09, 95% CI 1.92-4.95), 2) were to some
extent worried about developing cervical cancer (OR
1.92, 95% CI 1.32-2.80), 3) considered Pap smear screen-
ing very important to prevent cervical cancer (OR 3.50,
95% CI 1.64-7.50), or 4) were able to link the positive
test result with an STI (OR 1.70, 95% CI 1.17-2.45).
Women who felt they were in bad or very bad self-
perceived health (OR 0.49, 95% CI 0.27-0.91) or would
not tell a partner about the results (OR 0.21, 95% CI
0.09-0.48) had a significantly reduced odds of intent to
participate. When we tested for interaction terms be-
tween the letters and age, and the letters and civil status
in the univariable logistic model, there were no signifi-
cant effects (χ2 = 2.55, df = 4, p-value = 0.64 and χ2 =
1.02, df = 2, p-value = 0.60, respectively) and thus, the
variables were not included in the models presented in
Table 4.
Discussion
The results of this randomized survey suggest that nei-
ther a switch from Pap smear to HPV testing nor more
explicit information about the infectious nature of the
Table 1 Background characteristics of women randomized to one of three invitation letters to participate in cervical
cancer screening
Variables Survey randomization
Pap letter
(n = 1 168)
HPV basic letter
(n = 1 187)
HPV expanded letter
(n = 1 185)
Total
(n = 3 540)
Norwegian population*
Age (years), mean (SD) 45.3 (12.3) 45.3 (11.9) 44.7 (12.1) 45.1 (12.1)
Age distribution (years)
<30 147 (12.6) 126 (10.6) 155 (13.1) 428 (12.1) 11.1%
30-39 274 (23.5) 295 (24.9) 288 (24.3) 857 (24.2) 23.7%
40-49 278 (23.8) 308 (26.0) 301 (25.4) 887 (25.1) 24.8%
50-59 286 (24.5) 287 (24.2) 272 (23.0) 845 (23.9) 21.8%
60-69 183 (15.7) 171 (14.4) 169 (14.3) 523 (14.8) 18.6%
Personal income (Kroner) n = 1 079 n = 1 094 n = 1 108 n = 3 281
<200 000 134 (12.4) 127 (11.6) 135 (12.2) 396 (12.1) 22.5%
200 000–399 999 521 (48.3) 541 (49.5) 524 (47.3) 1 586 (48.3) 48.0%
400 000–599 999 371 (34.4) 361 (33.0) 373 (33.7) 1 105 (33.7) 20.8%
600 000–799 999 37 (3.4) 47 (4.3) 69 (6.2) 153 (4.7) 6.2%
≥800 000 16 (1.5) 18 (1.6) 7 (0.6) 41 (1.2) 2.5%
Geographic location
Oslo 293 (25.1) 325 (27.4) 284 (24.0) 902 (25.5) 27.8%
South East (excluding Oslo) 298 (25.5) 312 (26.3) 306 (25.8) 916 (25.9) 25.1%
South West 372 (31.9) 350 (29.5) 397 (33.5) 1 119 (31.6) 30.9%
North 205 (17.6) 200 (16.5) 198 (16.7) 603 (17.0) 16.2%
Civil status n = 1 104 n = 1 109 n = 1 108 n = 3 321
Single 319 (27.3) 283 (25.5) 311 (28.1) 913 (27.5) 28.7%
Married/Cohabiting 785 (67.2) 826 (74.5) 797 (71.9) 2408 (72.5) 71.3%
Education n = 1 168 n = 1 186 n = 1 184 n = 3 538
≤High school or vocational school 443 (37.9) 433 (36.5) 448 (37.8) 1 324 (37.4) 61.0%
≥Bachelor degree 725 (62.1) 753 (63.5) 736 (62.2) 2 214 (62.6) 39.0%
Born in Norway n = 1 165 n = 1 183 n = 1 183 n = 3 531
Yes 1 106 (94.9) 1 127 (95.3) 1 111 (93.9) 3 344 (94.7) n.a.
Values are numbers (percentages) unless otherwise stated.
CC, cervical cancer; HPV, human papillomavirus; n.a., not available; (NOK8.004 = €1).
*Statistics Norway (www.ssb.no/english).
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attendance. We cannot exclude the impact of HPV test-
ing on the strength of intent to participate as measured
on a scale; however, the effect is small and not likely to
be clinically relevant. Rather, our results from the multi-
variable regression model indicate that factors such as:
confidence in the benefits of screening, anxiety towards
developing cervical cancer, perceived risk and ability to
correctly interpret results have a greater impact on
intention to screen, beyond what changing the screening
test might induce.
Our results suggest that the ability to associate an
HPV infection as a sexually transmitted infection was
lacking, and the indifference to screening test method
may be influenced by this high level of unawareness withHPV. Nearly half of the women had never heard of HPV,
and the majority of women presented with the HPV
basic and expanded letter versions misinterpreted the
sexually transmitted nature of the infection, regardless
of being explicitly told in the invitation letter. Women
who received the Pap letter were also told in the letter
that most cellular changes were caused by an infection
with HPV—and were even less likely to state a connec-
tion between cellular abnormalities and the STI.
Women may be less able to accurately weigh the bene-
fits and harms of screening due to a lack of understand-
ing. In our sample, we found that the ability to correctly
interpret an HPV-test result was positively associated
with intention to participate, even after adjusting for
education. However, the effect of a more informed
Table 2 Responses for questions eliciting knowledge and anxiety by randomized group
Variables* Survey randomization
Pap letter
(n = 1 168)
HPV basic letter
(n = 1 187)
HPV expanded letter
(n = 1 185)
Total
(n = 3540)
Perceived health
Neither good nor bad 156 (13.4) 151 (12.7) 149 (12.6) 456 (12.9)
Bad/Very bad 52 (4.5) 44 (3.7) 34 (2.9) 130 (3.7)
Have had previous Pap smear
Yes 1 092 (93.8) 1 125 (95.1) 1 112 (94.2) 3 329 (94.3)
Have had previous dysplasia
Yes 245 (21.0) 266 (22.5) 257 (21.7) 768 (21.8)
Don't know 60 (5.2) 48 (4.1) 63 (5.3) 171 (4.8)
Primary cause of CC?
Genetics 245 (21.0) 254 (21.4) 244 (20.6) 743 (21.0)
A virus 514 (44.0) 477 (40.3) 493 (41.6) 1 484 (42.0)
Hormones 120 (10.3) 125 (10.6) 133 (11.2) 378 (10.7)
Smoking 9 (0.8) 12 (1.0) 10 (0.84) 31 (0.9)
Other 25 (2.1) 33 (2.8) 23 (1.94) 81 (2.3)
Don't know 254 (21.8) 284 (24.0) 281 (23.7) 819 (23.2)
Heard about HPV?
Yes 627 (53.8) 628 (53.0) 608 (51.4) 1 863 (52.7)
Believes HPV is transmitted througha
Air 0 (0.00) 4 (0.6) 4 (0.7) 8 (0.4)
Drinking water 1 (0.2) 1 (0.2) 2 (0.3) 4 (0.2)
Food 1 (0.2) 1 (0.2) 3 (0.5) 5 (0.3)
Sexual contact 526 (83.9) 505 (80.4) 496 (81.6) 1 527 (82.0)
Don't know 99 (15.8) 117 (18.6) 103 (16.9) 319 (17.1)
Worried about developing CC?
Very little or not at all 734 (62.9) 746 (63.0) 738 (62.4) 2 218 (62.7)
Some 372 (31.9) 378 (31.9) 369 (31.2) 1 119 (31.7)
Quite worried or very worried 61 (5.2) 61 (5.1) 76 (6.4) 198 (5.6)
Worried about developing STI?
Very little or not at all 1 032 (88.4) 1 046 (88.2) 1 050 (88.7) 3 128 (88.4)
Some 90 (7.7) 92 (7.8) 81 (6.8) 263 (7.4)
Quite worried or very worried 46 (3.9) 48 (4.1) 53 (4.5) 147 (4.2)
Importance of Pap smear to prevent CC?
Very little or not at all 15 (1.3) 21 (1.8) 20 (1.7) 56 (1.6)
Some 59 (5.1) 65 (5.5) 68 (5.7) 192 (5.4)
Quite important or very important 1 094 (93.7) 1 101 (92.8) 1 097 (92.6) 3 292 (93.0)
Values are numbers (percentages) unless otherwise stated.
CC, cervical cancer; HPV, human papillomavirus; STI, sexually transmitted infection.
*A maximum of 13 women (0.4%) chose not to answer on any given question.
aAnswering the question was contingent on having previously heard of HPV.
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the relationship is not necessarily causal. The women in
our study did not seem to be more anxious towards re-
ceiving a positive HPV result even though testing posi-
tive for an STI has been shown to be stressful and evokestigma. Even if present, studies have shown that over
time, HPV-positive related anxiety does not inflict add-
itional burden beyond what having an abnormal Pap
smear imposes [6,20]. It should be noted that regard-
less of test method, an overwhelming proportion of
Table 3 Primary results of intention to screen and follow-up abnormal results, anxiety and willingness to disclose
abnormal result, by randomized group
Variables* Survey randomization p-value
Pap letter
(n = 1 168)
HPV basic letter
(n = 1 187)
HPV expanded letter
(n = 1 185)
Intend to participate in CC screening?
Yes 92.3 (90.8-93.8) 91.8 (90.3-93.4) 92.2 (90.7-93.7) 0.906
How likely to participate? (scale 1–10)a
Mean (CI) 8.40 (8.27-8.54) 8.29 (8.15-8.41) 8.24 (8.10-8.36) 0.008b
Intend to participate in follow-up control?
Yes 97.6 (96.7-98.5) 97.1 (96.2-98.1) 97.2 (96.3-98.2) 0.751
How likely to participate in follow-up? (scale 1–10)a
Mean (CI) 9.34 (9.24-9.44) 9.14 (9.04-9.24) 9.16 (9.04-9.25) 0.002c
Worried about abnormal test result? 0.184
Not at all or very little 14.1 (12.1-16.1) 12.9 (11.0-14.8) 12.2 (10.3-14.0)
Some 46.9 (44.0-49.7) 45.3 (42.4-48.1) 45.9 (43.0-48.7)
Quite or very worried 39.0 (36.2-41.8) 41.8 (39.0-44.6) 42.0 (39.2-44.8)
Interpretation of positive test? <0.001
Unlikely/very unlikely I have an STI 70.4 (67.8-73.1) 63.5 (60.7-66.2) 60.4 (57.7-63.2)
Likely or very likely I have an STI 29.6 (27.0-32.2) 36.5 (33.8-39.3) 39.6 (36.8-42.4)
Would tell partner about test result? 0.913
Yes 91.8 (90.2-93.4) 92.1 (90.5-93.6) 92.4 (90.9-93.9)
Don't know 7.2 (5.7-8.7) 6.8 (5.3-8.2) 6.33 (5.0-7.7)
Would tell close friends about test result? 0.010
Yes 30.5 (27.9-33.2) 28.5 (25.9-31.1) 25.7 (23.2-28.2)
Don't know 39.5 (36.7-42.3) 36.2 (33.5-39.0) 39.7 (36.9-42.5)
Values are percentages (CI) unless otherwise stated.
CC, cervical cancer; CI, confidence interval; STI, sexually transmitted infection.
*A maximum of 19 women (0.5%) chose not to answer on any given question.
aCI for nonparametric distribution calculated by bootstrapping and using bias-corrected estimates.
bLetter 1 vs Letter 2: P-value = 0.05, Letter 1 vs Letter 3: P-value = 0.002.
cLetter 1 vs Letter 2: P-value = 0.002, Letter 1 vs Letter 3: P-value = 0.001.
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result. Additional analyses that address the appropriate
communication of results could help alleviate unneces-
sary anxiety for women faced with an abnormal test re-
sult. As expected, anxiety towards developing an STI
was inversely related to age and was lower among
women in committed relationships; however, this anx-
iety did not affect overall intention to participate. On
the other hand, women reporting anxiety towards de-
veloping cervical cancer were more likely to report
intention to participate. We also found that women
were slightly more hesitant to reveal a positive HPV result
to their close friends compared to a Pap smear result
(Table 3); yet, whether this suggests there is more stigma
associated with the HPV result is unclear as measuring
willingness to tell friends is a sub-optimal proxy for
stigma. Regardless of the effect on attendance, it is clear
that educational campaigns should accompany changes in
screening programs to ensure women are fully informed,understand what they are being screened for and how to
interpret their results.
Specific type of cervical cancer screening test may not
be one of the motivating (or de-motivating) factors that
influences participation. One possible explanation would
be if the rationale to attend screening in Norway stems
from a sense of duty. This "obligation factor” has been
tied to screening previously, and is often documented in
welfare countries where state-run health care systems
dominate [21]. In neighboring Sweden participation
rates in cervical cancer screening programs are similarly
high (over 90% participate at least once), but a reported
one-third of women were unaware of which type of can-
cer they were being screened for [22]. Similarly, publicly
provided screening programs have been documented to
increase the perceived value of the screening program
when compared to programs offered through a private
healthcare provider, where individuals may comply due
to the fact they trust the source of the recommendation
Table 4 Results of the univariable and multivariable logistic regression assessing factors associated with women who
are likely to participate in screening
Univariable model Multivariable model*
OR 95% CI p-value OR 95% CI p-value
Letter type 0.91 0.64
Pap letter 1 – 1 –
HPV basic letter 0.94 (0.69-1.27) 0.68 0.87 (0.61-1.24) 0.46
HPV expanded letter 0.99 (0.73-1.34) 0.934 1.01 (0.70-1.46) 0.92
Self perceived health 0.001 0.08
Good or very good 1 – 1 –
Neither good nor bad 0.80 (0.57-1.14) 0.22 0.97 (0.62-1.52) 0.91
Bad or very bad 0.41 (0.25-0.67) <0.001 0.49 (0.27-0.91) 0.02
Previous Pap smear
No/don't know 1 – 1 –
Yes 4.60 (3.24-6.53) <0.001 3.09 (1.92-4.95) <0.001
Primary cause of CC?
Doesn't know, (stated other than virus) 1 – 1 –
Virus 1.47 (1.13-1.90) 0.004 1.34 (0.97-1.84) 0.08
Worried about developing CC? <0.001 0.001
Very little or not at all 1 – 1 –
Some 2.03 (1.50-2.75) <0.001 1.92 (1.32-2.80) 0.001
Quite worried or very worried 2.53 (1.23-5.20) 0.01 2.65 (0.92-7.63) 0.07
Worried about developing an STI? 0.78 0.72
Very little or not at all 1 – 1 –
Some 1.18 (0.72-1.95) 0.50 0.96 (0.51-1.83) 0.91
Quite worried or very worried 1.08 (0.57-2.02) 0.82 0.71 (0.31-1.63) 0.42
Perceived risk of CC compared to others? <0.001 0.04
Lower 1 – 1 –
Same 1.67 (1.27-2.20) <0.001 1.47 (1.05-2.06) 0.03
Higher 3.64 (1.86-7.14) <0.001 2.13 (0.96-4.72) 0.06
Importance of Pap smear to prevent CC? <0.001 <0.001
Very little or not at all 1 – 1 –
Some 1.01 (0.52-1.96) 0.97 0.75 (0.33-1.73) 0.51
Quite important or very important 5.89 (3.24-10.69) <0.001 3.50 (1.64-7.50) 0.001
Interpret the results from a positive test?
Unlikely/Very unlikely STI 1 – 1 –
Likely/Very likely STI 2.13 (1.59-2.87) <0.001 1.70 (1.17-2.45) 0.005
Would tell partner about test result? <0.001 <0.001
Yes 1 – 1 –
No 0.15 (0.08-0.29) <0.001 0.21 (0.09-0.48) <0.001
Don't know 0.59 (0.39-0.89) 0.01 0.74 (0.44-1.23) 0.25
Would tell close friends about test result? <0.001 0.15
Yes 1 – 1 –
No 0.60 (0.44-0.82) 0.001 0.75 (0.52-1.09) 0.14
Don't know 0.96 (0.69-1.33) 0.79 1.02 (0.69-1.50) 0.92
CC, cervical cancer; CI, confidence interval; OR, odds ratio; STI, sexually transmitted infection.
*In addition to variables in the table, odds ratios (ORs) were adjusted for age, income, education, and civil status using listwise deletion of missing observations.
Model fit was good, indicated by a non-significant Hosmer-Lemeshow test (p-value = 0.15).
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sively publicly funded, qualitative research evaluating the
decision-making process surrounding screening uptake re-
vealed that some women likened the welfare state’s healthcare
system to a “mother” figure [24]. In addition, many women
may simply attend in order to have the personal reassurance
they are disease free. Any of the above reasons could provide
the basis that current participation rates could likely remain
high irrespective of future screening test method.
Previous knowledge of HPV was higher than what has
been previously reported in 2005 [7], though an increase
in awareness of HPV is expected given the media atten-
tion surrounding the introduction of the HPV vaccine in
Norway in 2009. Our sample’s self-reported history of hav-
ing had at least one previous Pap smear was in line with
age-specific rates reported in a recent survey and verified
using registry data [25]. Participation rates in Norway have
been shown to be influenced by civil status [26], not af-
fected by educational status and decrease with age [2,26].
We found similar trends for intention to participate in the
univariable model, though the effects were no longer sig-
nificant in the multivariable model, similar to the other
study [26]. The associations we obtained between know-
ledge, perceived risk, previous behavior and anxiety with
participation have previously been documented [27] and
our primary finding of no difference in willingness to par-
ticipate between primary cytology and HPV testing are
similar to those found in the POBASCAM [17] random-
ized controlled trial, where in fact, actual participation
rates in the trial increased compared to historic levels.
Limitations
Confounders and statistical variation between letter ver-
sions are likely minimized due to randomization and our
large sample size; however, generalizing our results to
the Norwegian population may be mitigated by 1) not
allowing all women adequate time to respond to the sur-
vey (due to the target number of women reached within
two weeks) and 2) the over representativeness of women
with a university education when compared to the
Norwegian population (Table 1). These factors may intro-
duce selection bias, particularly if non-responders are
more concerned with primary HPV-based screening than
responders. Nevertheless, the overall response rate was
greater than 50%, and intended participation was not af-
fected when we adjusted for educational attainment, add-
ing strength to the ability to generalize our study to the
Norwegian population. As expected, actual participation
rates recorded by the Cancer Registry of Norway [2] do
not reach the same magnitude as stated intention mea-
sured in our survey. It is a well-known maxim that what
people say is not what they actually do; therefore, our re-
sults are subject to hypothetical bias due to not measuring
actual behavior. In addition, capturing responses to ahypothetical positive test result may reduce the ability to
measure anxiety, as women may not internalize their re-
sult. Similarly, we cannot discount that women may have
only scanned the invitation letter without noticing the
switch in test method for those with the HPV invitation
letters. Consequently, the null effect of HPV testing on
participation may be due to the lack of careful reading and
whether there is an actual corollary of introducing the
new technology is not certain given that we measured
intention rather than action. In order to minimize survey
fatigue, we did not provide additional material to aid inter-
pretation of a positive HPV-result, but as any organized
screening program switches to primary HPV screening, it
is likely more in-depth material will accompany any posi-
tive result and could impact understanding.
Policy implications
It is important for policy-makers to gauge the impact pri-
mary HPV testing will have on attendance prior to imple-
mentation in Norway. Our findings are similar to results
from a previous study conducted within a large randomized
trial setting for primary screening [17] and to a contingent
value study conducted in the UK for HPV testing in a triage
setting [28]. The impact of introducing HPV as a primary
screening test on participation is small if at all present and
strengthens the argument for its implementation in
Norway, as evidence continues to grow suggesting that
HPV testing will likely not induce prolonged adverse
psychological effects. Larger health benefits in combin-
ation with less frequent screening intervals have been
shown to be less costly to society than the current Pap
smear-based program in Norway [29]. In addition, as half
of the cervical cancers in Norway are among those who
choose not to regularly participate in screening, attend-
ance in the program has the potential to increase if self-
sampling kits are sent to non-attenders [30], an opportun-
ity that is not as readily available with Pap smear-based
screening.
Conclusion
Results indicate that, in Norway, switching to primary
HPV screening, independent of additional information
on HPV infections, is neither likely to reduce screening
participation rates nor increase anxiety. However, women
lacked the proper interpretation of their HPV-test result
and it is uncertain whether increased awareness of HPV
and its implications will impact future participation rates
in primary HPV screening programs.Additional file
Additional file 1: Translated survey invitations letters and
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